BioSig Technologies, Inc. (BSGM)
NASDAQ: BSGM · Real-Time Price · USD
2.180
+0.240 (12.37%)
At close: May 12, 2025, 4:00 PM
2.250
+0.070 (3.21%)
After-hours: May 12, 2025, 7:58 PM EDT
BioSig Technologies Revenue
In the year 2024, BioSig Technologies had annual revenue of $40.00K with 122.22% growth. BioSig Technologies had revenue of $13.00K in the quarter ending December 31, 2024, with 8.33% growth.
Revenue (ttm)
$40.00K
Revenue Growth
+122.22%
P/S Ratio
1,321.76
Revenue / Employee
$8,000
Employees
5
Market Cap
52.87M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 40.00K | 22.00K | 122.22% |
Dec 31, 2023 | 18.00K | -268.00K | -93.71% |
Dec 31, 2022 | 286.00K | -155.00K | -35.15% |
Dec 31, 2021 | 441.00K | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BSGM News
- 7 days ago - BioSig Enters into an LOI to Merge with Streamex Exchange Corp. - GlobeNewsWire
- 6 weeks ago - BioSig Technologies Confirms Full Compliance with Nasdaq Requirements for Continued Listing on The Nasdaq Capital Market - GlobeNewsWire
- 6 months ago - BioSig Regains Compliance with Nasdaq's Minimum Bid Price Requirement - GlobeNewsWire
- 7 months ago - BioSig Technologies' Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel - GlobeNewsWire
- 10 months ago - BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation - GlobeNewsWire
- 10 months ago - BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024 - GlobeNewsWire
- 1 year ago - BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer - GlobeNewsWire
- 1 year ago - BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire